November 2025

BURJEEL
HOLDINGS

Earnings Presentation

Q3 & 9M 2025 Results

Leading Super-Specialty Healthcare Provider in MENA

Disclaimer

This presentation has been prepared by Burjeel Holdings PLC based on publicly available information and non-public information to assist you in making a preliminary analysis of the content referenced herein solely for informational purposes. It should not be construed as an offer to sell or a solicitation of an indication of interest to purchase any equities, security, option, commodity, future, loan or currency including a private sale of shares in the Company **(the "Financing Instruments").**

It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third-party evaluation of any Financing Instrument or any offering of them and should not be considered as a recommendation that any recipients should subscribe for or purchase any Financing Instruments. The recipient agrees to keep confidential any information contained herein and any other written or oral information otherwise made available in connection with any potential transaction related to this presentation and shall not reproduce, publish, distribute or otherwise divulge such information to any other person(s) other than in accordance with any applicable non-disclosure agreements executed by the recipient with the Company.

None of the Company or its subsidiaries or any of their affiliates or advisors make any representation or warranty as to the fairness, accuracy, adequacy or completeness of the information, the assumptions on which it is based, the reasonableness of any projections or forecasts contained herein or any further information supplied or the suitability of any investment for your purpose. None of the Company or any of its affiliates or advisors, or their respective directors, officers or employees, share any responsibility for any loss, damage or other result arising from your reliance on this information. Each of the Company, its subsidiaries, their affiliates and advisors therefore disclaim any and all liability relating to this presentation including without limitation any express or implied representations or warranties for statements contained in, and omissions from, the information herein. No recipient of this presentation should rely upon any information contained in this presentation, including but not limited to any historical financial data, forward-looking statements, forecasts, projections or predictions. The Company, its subsidiaries, their affiliates and advisors are acting solely in the capacity of an arm's-length counterparty and not in the capacity of your financial advisor or fiduciary. Nothing in this presentation should be construed as legal, tax, regulatory, accounting or investment advice. The recipients should seek and rely upon the advice of their own professionals and other advisors for such matters.

Key Highlights

Leading Super-Specialty Healthcare Provider in MENA

Q3'25: Built on Strength — Record Performance

BURJEEL HOLDINGS

Financial Highlights

Revenue

Q3'24	Q2'25	Q3'25
AED1,319m	AED1,403m	AED1,422m
+14.1% YoY	+18.7% YoY	+7.9% YoY

EBITDA (% Margin)

Q3'24	Q2'25	Q3'25
AED273m	AED306m	AED320m
20.7%	21.8%	22.5%

Net profit (% Margin)

Q3'24	Q2'25	Q3'25
AED137m	AED148m	AED175m
10.4%	10.5%	12.3%

Strategic Focus	Execution Highlights	Impact (Q3'25)	Mid-term Outlook
Optimize Utilization	• Optimized patient flow and capacity alignment across network brands	• Outpacing population growth with 15% YoY increase in high-end segment revenue	• Achieve >80% bed occupancy and sustain >12% Group revenue CAGR through optimized capacity mix
Ramp-Up of New Assets	• 45+ new healthcare assets now operational under the ramp-up plan	• Higher revenue, lower cost pressure — OPEX ratio down 6.2 p.p. QoQ	• Reach breakeven across all new sites by end-2026 via staffing efficiency and integrated patient pathways
Enhance Case Mix	• Shift toward high-acuity, surgical, and complex cases	• Oncology surgeries up 41% YoY, reflecting an improved surgical mix	• Expand complex-care portfolio to sustain single-digit patient yield CAGR and reinforce specialty leadership
Efficiency Gains	• Streamlined workforce, marketing, and procurement efficiency	• Only 30 doctors added YTD vs 188 in FY2024; marketing spend down 46% from Q4'24 peak	• Achieve >25% EBITDA margin across hospitals and medical centers via scale efficiencies and automation rollout
Advance Expansion	• Ongoing expansion across UAE and KSA networks in line with the guidance	• 12 assets added YTD; ~16 under development: 65% of FY2025 growth CAPEX deployed	• Prioritize high-ROI growth in KSA and Northern Emirates to normalize ROCE from 13% toward 15%+

Recent **Medical Developments**

Performed GCC's First HAIP Surgery

Conducted a cytoreductive surgery with HIPEC for stomach cancer and the GCC's first Hepatic Artery Infusion Pump (HAIP) implantation for liver tumors, cementing the Group's leadership in complex and precision oncology.

Achieved Gulf's First Uniportal Robotic Lobectomy

Performed the region's first Uniportal Robotic Lobectomy using the Da Vinci Xi system through Burjeel's Advanced Thoracic Surgery team, expanding the Group's robotic-assisted surgical capabilities and advanced, low-morbidity procedure portfolio.

Expanded Precision Medicine Capabilities

Broadened access to pharmacogenomics testing and biosimilars to enable more personalized, effective treatments for chronic and oncology patients, strengthening the Group's position in evidence-based, patient-centered care.

Launched Interventional Pain Management Center

Opened a new Interventional Pain Management Center at Burjeel Hospital for Advanced Surgery, Dubai, delivering targeted, minimally invasive treatments for spine, joint, and cancer-related pain, enhancing multidisciplinary, outcome-driven care.

Da Vinci Xi
800
Robotic Surgeries
Since Inception

Multi-Organ
63
Transplants
Since Inception

Oncology
630
Surgeries
(+106% YoY)
9M 2025

Dr. Paley Clinic
395
Surgeries
(+38% YoY)
9M 2025

BURJEEL HOLDINGS

Differentiated Growth Strategy
Driving Specialized Care Across Network



- **Anchor Burjeel as the MENA referral hub**, attracting complex cases and exporting world-class expertise.
- **Expand community-driven, value-based care** to capture early-stage patients and channel referrals system-wide.
- **Convert referrals into specialized care pathways** through integrated secondary and tertiary hospitals.
- **Position BMC as the GCC's premier hub** for complex, sub-specialty care.
- **Scale day care & specialized centers** to relieve hospital load and expand access in underserved markets.
- **Deploy a GCC-wide screening network** to detect, stratify, and route high-acuity patients.

Burjeel Holdings Today

112 Healthcare assets incl. 20 hospitals

15 O&M projects in UAE & Africa

1,784 Bed capacity

1,774 Doctors

Regional Footprint Across GCC & Africa



BURJEEL
HOLDINGS

Expanding Reach, Enhancing Care:
Disciplined Execution Across Growth Pipeline

2025

- Advanced Oncology Center (Dubai)
- Medical Center, Al Falah (Abu Dhabi)
- Medical Center, Saadiyat (Abu Dhabi)
- Medical Center, Silicon Oasis (Dubai)
- Medical Center, Al Wasn (Dubai)

2026

- Acute Care Hospital, DIP (Dubai)
- Day Surgery Center, Riyadh (KSA)
- Day Surgery Center, Al Zakhir (Al Ain)
- Trust Fertility Clinic (Al Ain)
- Medical Center, Gayathi (Abu Dhabi)
- Day Surgery Center (Ras Al-Khaimah)
- Medical Center, Al Riyadh (Abu Dhabi)
- Medical Center, Al Yahar (Al Ain)
- Day Surgery Center, Al Quo (Al Ain)
- Medical Center, Al Fouah (Al Ain)
- Day Surgery Center, Al Reeman (Abu Dhabi)
- Day Surgery Center, Al Khobar (KSA)

2027

- LLH Hospital, Jebel Ali (Dubai)
- Trust Fertility Clinic (Dubai)

Expected Impact at Maturity

- **AED 1.5 bn** Revenue
- **~25%** EBITDA
- **3-5 years** Maturity
- **AED 1.0 bn** CAPEX

برجيل
burjeel

19 Healthcare Assets

- Completed
- Under Construction
- Planning & Design

Note: Excludes 6 LLH Medical Centers & Clinics (Abu Dhabi & Al Ain) and 1 Medeor Medical Center (Abu Dhabi) opened in 9M'25. The list also doesn't include over 30 planned PhysioTherabia Centers expected to open by 2026.

BURJEEL
HOLDINGS

Performance Review

Leading Super-Specialty Healthcare Provider in MENA

Outpacing the Market:
Proven Leadership, Resilient Growth

Group Outpatient Footfall, k



- **Total patient footfall** rose 4.6% in Q3'25 and reached 5.1 million in 9M'25, up 7.3%, reflecting robust demand and the strength of Burjeel Holdings' network.
- **The Group outpaced** regional population growth, underscoring its market leadership despite temporary access restrictions[1] at premium facilities to one of the major Abu Dhabi-based insurers since May 2025.
- **Quarterly performance** was driven by a stronger case mix, growth in high-value specialties, and new direct corporate contracts.
- **Outpatient footfall** grew 4.5% in Q3'25, supported by the ramp-up of primary care and physiotherapy centers and steady demand across orthopedics, urology, neurology, pulmonology, and IVF.
- **Outpatient utilization** eased to 66%, reflecting new physician onboarding and creating capacity for future patient growth.

Group Inpatient Footfall, k



- **Inpatient footfall** grew 8.4% in Q3'25, driven by strong performance across oncology, cardiology, gastroenterology, and orthopedics.
- **The Oncology segment** achieved notable conversion gains, performing over 200 surgeries (+41%) and 2,500 radiotherapy sessions (+21%) in Q3'25, underscoring the Group's growing strength in complex cancer care.
- **Total surgeries** reached 67,050 in 9M'25, up 10.3%, reflecting strong momentum across Burjeel Medical City, Burjeel Specialty Hospital Sharjah, Lifecare Hospital Musaffah, and Medeor Hospital Abu Dhabi.
- **Inpatient volumes** rose 12.4% in 9M'25, with bed occupancy at 68% in Q3 and 67% for 9M'25, reflecting recent capacity additions (+54 beds) and highlighting ample room for further network growth.

Note: (1) Temporary access restrictions for select insurance plans in Abu Dhabi were resolved effective November 1, 2025, following successful completion of policy updates.

Record Quarterly Financial Performance
With Margins Expanding Across the Network

BURJEEL HOLDINGS

Group Revenue, AED m



YoY

+7.9%

Hospitals	+55
Medical Centers	+15
Pharmacies	(3)
Others	+37

- **Group Revenue reached a record high** in Q3'25, driven by patient footfall growth and an improved case mix across the network.
- **Premium and self-paying inflows**, along with complex care growth, offset Burjeel-initiated basic-segment access restrictions effective 1st May 2025.
- **Hospital revenue** grew 4.6%, while **Medical Centers** rose 15.8%, supported by the ramp-up of new facilities and service lines.



YoY

+10.6%

Hospitals	+278
Medical Centers	+63
Pharmacies	(1)
Others	+54

- **Top-line growth** in 9M'25 was driven by sustained patient footfall in Q3'25 and improved patient yield.
- **Oncology revenue** rose 29.4%, supported by higher surgical volumes and advanced treatment conversions, while other key specialties (IVF, urology, cardiology, and gastro) also delivered solid growth.
- **Hospital revenue** increased 8.3%, and **Medical Centers revenue** rose 22.9%
- **Other revenue** grew 130.2%, reflecting continued expansion of O&M activities.

Group EBITDA, AED m



YoY

+17.1%

Hospitals	+54
Medical Centers	(8)
Pharmacies	+1
Others	(0.5)

- **Group EBITDA** grew 17.1% in Q3'25, with the margin improving by 1.8 p.p.
- **EBITDA margin expansion** was fully operational, reflecting a higher contribution from complex and specialized medical services, driven by cost discipline and operating leverage across ramped-up and maturing assets.
- **Hospitals EBITDA** increased 20.1%, with the margin improving to 25.8% from 22.5%.



YoY

+15.3%

Hospitals	+105
Medical Centers	(29)
Pharmacies	1
Others	+30

- **Group EBITDA** increased 15.3% in 9M'25, underpinned by strong operational performance and asset ownership optimization completed in Q2[1].
- **Group EBITDA** also reflected continued sub-specialty investments and AED 49 million in ramp-up losses from over 45 newly opened healthcare assets.
- **Hospitals EBITDA** rose 14.0%, with the margin improving to 23.7% (+1.2 p.p.).
- **Medical Centers EBITDA** was impacted by AED 29 million in ramp-up costs from newly launched facilities across the UAE and KSA.

Breakdown in change, AED m: Hospitals, Medical Centers, Pharmacies, Others

Note: (1) Includes AED 72 million gain from asset optimization following the Dubai Medeor Hospital building acquisition, completed in June 2025, reflecting lease liability derecognition.

BMC Strengthens Profitability
Through Scale & Operational Excellence

Total patients, k



Revenue, AED m[1]



EBITDA, AED m[1]



Burjeel Medical City (BMC) delivered 7.1% revenue growth in Q3'25, driven by a 13.9% rise in patient volumes, higher outpatient share, improved surgical conversion, and sustained momentum in super-specialty services, despite temporary access restrictions for select insurance plans in Abu Dhabi. Bed occupancy stood at 58% in Q3'25, reflecting the addition of 34 new beds and providing headroom for future growth. **BMC EBITDA grew 46.8%,** supported by scale efficiencies and disciplined cost management, achieving **a record-high quarterly EBITDA margin of 22.0%.**

Note: (1) The above figures are pre-intersegment eliminations.

Trust Fertility Center: Powering UAE's Fertility Strategy with Rapid Ramp-Up

Integral in Burjeel's Women's Health Platform

Operational Since **Dec 2024**

Capacity **5,000 IVF cycles/year**

Net Profit Breakeven **Within 6 Months of Launch**

9M 2025 Ramp-Up Single-Digit EBITDA Margin at 30% Utilization

Trust Fertility Clinic

9M 2025

- **AED 40m** Total Revenue
- **2,500+** Unique Patient Volumes
- **1,600+** IVF, FET, & IUI Cycles Initiated
- **~50%** Clinical Pregnancy Rate (above global average)

Advanced IVF & Fertility Solutions

- Egg Retrieval
- AI-Driven Embryo Selection & AI-Assisted Sperm Selection
- Embryo Transfer
- Fertility Assessments
- Intrauterine Insemination (IUI)
- Ovarian Tissue Cryopreservation (OTC) for Oncology Patients
- Social Egg Freezing
- IVF Consultations
- Reproductive Medicine Consultations
- Laparoscopic Surgery
- Advanced Cryopreservation Storage System

Growth & Integration Priorities

Next Launch
Al Ain IVF Center (2026)
Dubai IVF Center (2027)

Strengthening Referrals
from BMC (Ob-Gyn, Endocrinology)

Preparing for Center of Excellence
(CoE) Designation in 2025

Expanding Collaboration
with Oncology, Urology, and Genetics

Continuous Staff Development
& Academic Leadership

Delivering Profitable Growth Through Scale & Cost Discipline

Group OPEX Breakdown, % of Revenue



Group EBITDA Analysis, AED m



- **Doctors’ and other employees’ salaries** as a share of revenue decreased by 0.9 p.p. YoY in Q3’25, reflecting more efficient workforce planning, improved physician utilization, and sustained administrative cost optimization. While 9M’25 personnel expenses remained broadly stable, the onboarding of only 30 new doctors this year indicates that the Group is now well-invested in medical capacity, supporting ongoing margin improvement and operating efficiency.
- **Inventory** as a share of revenue decreased by 2.6 p.p. YoY in Q3’25 and by 0.8 p.p. in 9M’25, supported by stronger procurement discipline, optimized supplier terms, and a shift toward higher-value procedures that lowered consumable intensity.
- **ECL provisions** remained stable at 3.5% of revenue in Q3’25, consistent with H1’25 levels and aligned with global healthcare peers. With collections strengthening, provisioning is expected to remain stable around current levels.

- **Other overhead expenses** continued to decline QoQ in Q3’25, standing 12.6% below the Q4’24 peak, confirming a sustainable cost-normalization trend. In 9M’25, overheads remained flat YoY as a share of revenue, reflecting efficiency gains and stronger cost discipline across the Group.
- **Q3’25 Group EBITDA** grew 17.1% YoY to AED 320 million, with margin expanding to 22.5% from 20.7% in Q3’24. **9M’25 EBITDA** increased 15.3% YoY to AED 807 million, driven by strong operational performance in Q2 and Q3 and the completion of asset ownership optimization earlier in the year.
- **9M’25 EBITDA** reflects AED 49 million in ramp-up losses from over 45 new physiotherapy, mental health, and day-surgery centers across the UAE and KSA. Now operational, these facilities are nearing break-even and supporting sustained profitability growth.

Robust Cash Flow Conversion & Net Profit Expansion

Cash Flow from Operating Activities, AED m



AED m	2021	2022	2023	2024	9M'24	9M'25
EBITDA[1]	779	878	1,018	959	700	807
Change in NWC	(196)	(429)	(382)	(343)	(310)	(410)
Maintenance CAPEX	(86)	(83)	(113)	(127)	(77)	(102)
Free Cash Flow[2]	497	366	523	489	313	295

Group Net Profit Analysis, AED m



- **Net profit** rose 27.5% in Q3'25, with the margin improving to 12.3% from 10.4%, driven by strong operating leverage and slower growth in non-operating expenses.
- **Operating cash flow** declined by AED 64 million to AED 244 million in 9M'25, mainly due to higher working capital outflows. **The change reflected a AED 143 million swing in payables**, as the Group accelerated supplier settlements to normalize payment cycles below 200 days and secure better terms.
- **Days payable outstanding** decreased to 213 from 244, while **days sales outstanding** increased slightly to 136 from 128.
- **Maintenance CAPEX** remained in line with guidance, while **growth CAPEX** totaled AED 474 million, covering strategic M&A transactions.

Notes: (1) Adjustments for one-offs apply only to FY 2024-2023 EBITDA and not to not quarterly data. These include Employee & BoD performance bonuses for FY'23 (paid in H1'24) and fair value movements on tradable investments, recorded in Dec'23 and divested in June'24. (2) FCF = EBITDA – maintenance CAPEX – change in working capital. Working capital = inventory + receivables – payables (incl. accruals). Change in working capital is calculated as working capital balance in prior period less working capital balance in current period.

Well-Capitalized Balance Sheet
Supporting Future Growth & Value Creation

AED m	FY 2023	FY 2024	9M'25
Bank balances and cash	**170**	**238**	**150**
Interest-bearing loans and borrowings	1,164	1,208	1,773
Bank overdrafts	–	–	–
Bank debt[1]	**1,164**	**1,208**	**1,773**
Net debt	**994**	**970**	**1,623**
Lease liabilities[2]	1,170	1,456	1,187
Net debt including lease liabilites[3]	**2,164**	**2,426**	**2,810**
Amounts due from / (to) related parties	(16)	(44)	(54)
KPIs:			
Net debt / pre-IFRS 16 LTM EBITDA[4]	**1.1x**	**1.3x**	**1.9x**
Total Group equity	**1,557**	**1,842**	**2,021**
Divided mainly into:			
Share capital	521	521	521
Share premium	367	367	367
Retained earnings (incl. NCI)	663	948	1,127

Debt Maturity as of 30 September 2025



Commitment to Conservative Financial Policy

- **Net debt / pre-IFRS 16 LTM EBITDA ratio** as of 30 September 2025 stood at 1.9x, reflecting growth CAPEX tied to network expansion in the UAE and Saudi Arabia, and the AED 186 million acquisition of the Dubai hospital building — a strategic investment expected to enhance operating leverage over time.
- **No contingent off-balance-sheet** liabilities.
- **A planned Sukuk issuance**, subject to shareholder approval and market conditions, is earmarked for loan repayment and mid-term growth funding.
- **The Group's balance sheet remains well-capitalized** with total equity rising to AED 2,021 million as of 30 September 2025 This strong financial position provides resilience and flexibility to support future growth and value creation.

Notes: (1) Includes interest-bearing loans and borrowings and bank overdrafts. (2) Includes current and non-current portion of lease liabilities. (3) Includes net debt and lease liabilities. (4) Pre-IFRS 16 EBITDA is calculated as reported EBITDA less annual lease rental, and net debt is calculated as bank debt less cash and bank balances.

Guidance

Leading Super-Specialty Healthcare Provider in MENA

Maintaining Growth Momentum While Building Future Margin Strength

	FY 2025 (Updated)	Mid-term (2026-2028)
Expansion	• **UAE:** 1 Advanced Care Oncology Center, 3 Burjeel Medical Centers, 6 LLH Medical Centers & Clinics, 1 Tajmeel Medical Center, 1 Medeor Medical Center	• **UAE:** 1 Burjeel Hospital, 1 LLH Hospital, 4 Burjeel Day Surgery Centers, 2 Trust Fertility Clinics, 4 Burjeel Medical Centers • **KSA:** 2 Burjeel Day Surgery Centers, 30 PhysioTherabia Centers
Revenue	• **Group revenue** expected to grow **~9% YoY**, despite temporary restrictions for certain insurance plans in Abu Dhabi[1] ◦ **BMC revenue** to grow in line with Group growth	• **Group revenue growth** to normalize gradually from **the mid-teens to low double-digits** over time as key assets mature, including: ◦ **BMC** revenue to reach **AED 2bn** revenue p.a. ◦ **Expansion projects** to reach **AED 1.7bn** revenue p.a.
EBITDA	• **Group EBITDA margin** expected to improve YoY to **over 19%**, reflecting operational momentum alongside strategic investments ◦ **BMC EBITDA margin** to improve to over **17%**	• **Group EBITDA margin** to gradually expand to **25%-27%** • **Driven by** ramp-up of growth assets, asset-light international expansion, as well as focus on increasing patient yield and operational excellence
CAPEX	• **Maintenance CAPEX** to be **<2.5%** of revenue • **Additional total investment** of **~AED 450m**[2] for UAE & KSA expansion and digital transformation	• **Maintenance CAPEX** to be **<2.5%** of revenue • **Additional total investments (2026-28)** of **~AED 600m** expected **until 2028** to drive UAE & KSA expansion and digital transformation
Leverage	• **Net leverage**[3] of **<2.5x** to be maintained • **Net leverage**[3] of **1.3x** as of December 2024	• **Net leverage**[3] of **<2.5x** to be maintained
Dividends	• **Payout ratio of 40-70%** of net income, dependent on required investment for potential additional growth	• **Payout ratio of 40-70%** of net income, dependent on required investment for potential additional growth

(1) Temporary access restrictions for select insurance plans in Abu Dhabi were resolved effective November 1, 2025, following successful completion of policy updates.
(2) Excludes investments related to the Dubai Medeor hospital building acquisition (AED 186 million).
(3) Calculated using pre-IFRS 16 EBITDA as EBITDA less annual lease rental payments.

Q&A

Appendix

Leading Super-Specialty Healthcare Provider in MENA

Group & Segment Financial Summary

Group Financial Summary

AED millions	Q3'25	Q3'24	9M'25	9M'24
Revenue	**1,422**	**1,319**	**4,099**	**3,705**
Inventories consumed	(312)	(323)	(985)	(920)
Doctors' and other employees' salaries	(590)	(559)	(1,789)	(1,609)
Provision for expected credit losses	(50)	(29)	(144)	(75)
Other general and admin expenses	(147)	(139)	(448)	(404)
Share of profit from associates	(4)	5	3	12
Other Income[1]	—	—	—	(10)
Change in financial assets carried at fair value through profit and loss	—	—	72	—
EBITDA	**320**	**273**	**807**	**700**
Finance costs	(37)	(35)	(121)	(104)
Depreciation & amortization	(89)	(88)	(284)	(258)
Provision for taxes	(19)	(13)	(40)	(31)
Net profit[3]	**175**	**137**	**362**	**306**

Segmental Financial Summary

AED millions	Q3'25	Q3'24	9M'25	9M'24
Revenue	**1,422**	**1,319**	**4,099**	**3,705**
Hospitals[2]	1,247	1,192	3,618	3,340
Medical Centers[2]	111	96	340	277
Pharmacies[2]	13	16	46	47
Others[3]	52	15	95	41
EBITDA	**320**	**273**	**807**	**700**
Hospitals	321	268	857	752
Medical Centers[4]	11	18	29	58
Pharmacies	2	1	4	3
Others[5]	(14)	(13)	(83)	(113)
Net profit	**175**	**137**	**362**	**306**
Hospitals	203	144	472	389
Medical Centers	0.4	10	(3)	32
Pharmacies	1	0.3	4	2
Others	(30)	(17)	(111)	(117)

Notes: Figures reflect reported EBITDA and net profit. (1) Includes AED 72 million gain from asset optimization following the Dubai Medeor Hospital building acquisition, completed in June 2025, reflecting lease liability derecognition. (2) Includes other operating income and other revenue represents the non-clinical revenue in the Hospitals, Medical Centers and Pharmacies segments which mainly include an O&M fee, a fee for manpower supply contracts, and several other items. (3) Others contains revenue from entities that mainly provide services to the Group's hospitals, medical centers and pharmacies and also includes centralized purchasing, claim care and valet parking. (4) Affected by the ramp-up of recently opened facilities in the UAE and KSA. (5) The Others segment includes head office and corporate expenses.

BURJEEL HOLDINGS

IR Contacts

November 2025

Sergei Levitskii

Director of Investor Relations

sergei.levitskii@burjeelholdings.com

ir@burjeelholdings.com

T: +971 2 3041 111

F: +971 2 2222 363

M: +971 503802383

PO Box 7400, Abu Dhabi, UAE

Investor Calendar

Company Website

Investor Feedback Hotline

Engaging openly with our investors and analysts is a cornerstone of our approach. We've partnered with Closir to make sharing your feedback quick and secure. Stakeholders can connect with us anytime — anonymously or directly.

Your voice matters — let's keep the dialogue open.

Investor & Analyst Feedback Portal